Navigation Links
Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
Date:3/4/2009

TSX Venture: QPT

EDMONTON, March 4 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or the "Company") a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced results from a study designed to investigate the effectiveness of its proprietary SL052 for photodynamic therapy (PDT) used in combination with immunotherapeutic agents in solid tumor animal models. The study, conducted by Dr. Mladen Korbelik at the BC Cancer Agency in Vancouver, demonstrated that SL052 increased the potency and effectiveness of immunotherapeutic agents when used in combination with SL052 PDT.

The results also confirmed that SL052 was an effective and well tolerated photosensitizer for PDT ablation of two highly tumorigenic, solid murine tumors. Further, the results demonstrated that photodynamic therapy generated direct local cytotoxicity and induced a systemic immune response, which could enhance its therapeutic effect on both primary tumors and metastases at distant sites.

The study tested several applications of SL052 and evaluated host recognition and immunological destruction of solid tumors. The results indicate the potential of SL052 PDT for use in combination with cancer vaccines to generate a superior immune response compared with vaccines alone. The study also revealed that SL052 PDT may be effectively combined with either single or multiple-complementary effectors of the host's immune response to substantially boost the frequency of permanent cures.

"The effects of immunotherapy can be amplified when combined with photodynamic therapy, potentially making immunophotodynamic therapy a superior systemic cancer treatment modality," said Thomas Woo, Vice President of Product Development at Quest.

SL052 is a non-toxic agent with broad potential to treat a variety of solid tumors using photodynamic (light activation) therapy or son
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 PlaqueTec ... Erfassung biologischer Daten in Verbindung mit Herzerkrankungen ... Das LBS nimmt gleichzeitig mehrere Blutproben von ... und sucht erhöhte biologische Aktivitäten in erkrankten ... Entdeckung und Entwicklung neuer Medikamente und Therapeutika ...
(Date:7/28/2014)... July 28, 2014 “2014 ... Lubricant Industry” is a professional and in-depth ... market. The report introduces Lubricant basic information, ... chain structure and industry overview. This research ... domestic market as well as global industry ...
(Date:7/28/2014)... 2014 /PRNewswire/ -   JOLT , a leading technology ... join its growing portfolio of startups. Next-level tech and ... JOLT accelerator, and Cohort four is no ... Since its launch in July 2012, JOLT ... of financing. Now at 23 investments, JOLT,s portfolio has ...
(Date:7/28/2014)... --  Propeller Health , the FDA-cleared digital health solution ... Brad Towle as Senior Vice President, Business and ... company,s sales growth, customer acquisition and program expansion. ... past role in the development of accountable care organizations, ... time in the industry," said David Van Sickle ...
Breaking Biology Technology:PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... Study Impact on Detroit Area, DETROIT, March ... findings from its new study, Affordable Broadband:,Empowering Communities ... expanded access to education, health care and civic,involvement ... Detroit Digital Empowerment Council (DEC) that was launched,earlier ...
... LEXINGTON, Mass., March 11 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... the Cowen and Company 28th Annual Health Care Conference, ... conference is being held in,Boston, Massachusetts. The presentation will ... the Investors section of the Indevus website at, http://www.indevus.com ...
... Immucor, Inc., a,global leader in providing automated ... today that it has signed a definitive,agreement ... held company,based in Warren, NJ that has ... enable rapid and comprehensive antigen,determination for donors ...
Cached Biology Technology:Study Finds Broadband Access Key to Empowerment of Minority Communities 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 3Immucor To Acquire BioArray Solutions Ltd. 2Immucor To Acquire BioArray Solutions Ltd. 3Immucor To Acquire BioArray Solutions Ltd. 4
(Date:7/28/2014)... the bug hunter, but the target of his work ... identified with special methods and instruments. Benjamin Hause, an ... Laboratory at Kansas State University, recently published an article ... is an important find in the United States. , ... know what it was," Hause said. "We used next-generation ...
(Date:7/28/2014)... -- Research and Markets has announced the ... 2014-2018" report to their offering. ... analyze biological data. These systems capture biological traits such ... and hand measurements from the subject and compare the ... purpose of a biometrics system is to identify and ...
(Date:7/28/2014)... RENO Norwegian explorer Roald Amundsen became the first ... 1911. More than 100 years later, an international team ... Research Institute (DRI) have proven that air pollution from ... 16 ice cores collected from widely spaced locations around ... created the most accurate and precise reconstruction to date ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Biometrics Market in Latin America 2014-2018 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
... The 8th International Conference on Biotherapy (ICB-2010) will ... at the Universal - Los Angeles Hilton. It ... new clinical and research findings in biotherapy (living ... the 4-day conference, an internationally distinguished faculty will ...
... Scientists of the Max Delbrck Center for Molecular ... Research Center (ECRC) of MDC and Charit in ... of epithelial cells and their molecular repertoire. Dr. ... have identified a transcription factor (grainyhead-like 2, Grhl2), ...
... study that sounds a conservation alarm for the world,s vertebrate ... better, says a University of New Hampshire researcher who was ... UNH research professor of natural resources and director of the ... to "The Impact of Conservation on the Status of the ...
Cached Biology News:International Conference on Biotherapy to be held in the US 2New insights into the development of epithelial cells 2UNH's Fred Short adds seagrass data to major conservation study 2
POU domain, class 2, transcription factor 2,...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Biology Products: